Literature DB >> 9933441

Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE).

J F Viallard1, J L Pellegrin, V Ranchin, T Schaeverbeke, J Dehais, M Longy-Boursier, J M Ragnaud, B Leng, J F Moreau.   

Abstract

We investigated the production of IL-2, IFN-gamma, IL-10 and IL-4 by PBMC from 24 patients with SLE and 10 healthy individuals. Basal and mitogen-stimulated (lipopolysaccharide and phytohaemagglutinin (LPS + PHA)) cytokine production was determined in a whole blood assay (WBA). Supernatants were collected and assayed with specific ELISAs. Although the IL-2 and IFN-gamma contents did not differ significantly between patients and controls under both conditions, statistically significant correlations were found between each cytokine and disease activity (SLAM index) after stimulation (respectively, r = 0.501, P = 0.01 and r = 0.631, P = 0.001). PBMC IL-10 production was significantly higher for patients than controls (P = 0.05), but no correlation between IL-10 levels and the SLAM index was obtained. IL-4 production was not statistically different between SLE patients and controls. For stimulated WBAs, the IL-10/IL-2 and IL-10/IFN-gamma ratios were significantly correlated with disease severity (P = 0.02; P = 0.001, respectively). Overall, our data suggest that SLE is characterized by an elevated production of IL-10, reflecting the basal state of activation of the immune system. During exacerbation of SLE, IL-2 and IFN-gamma are synthesized in larger amounts and may cause the tissue damage observed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933441      PMCID: PMC1905189          DOI: 10.1046/j.1365-2249.1999.00766.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

1.  Valid estimation of IL2 secretion by PHA-stimulated T-cell clones absolutely requires the use of anti-CD25 monoclonal antibody to prevent IL2 consumption.

Authors:  E Claret; J C Renversez; X Zheng; T Bonnefoix; J J Sotto
Journal:  Immunol Lett       Date:  1992-07       Impact factor: 3.685

2.  A "primary" antiphospholipid syndrome?

Authors:  R A Asherson
Journal:  J Rheumatol       Date:  1988-12       Impact factor: 4.666

3.  IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages.

Authors:  R T Gazzinelli; I P Oswald; S L James; A Sher
Journal:  J Immunol       Date:  1992-03-15       Impact factor: 5.422

4.  Human TH1 and TH2 subsets: doubt no more.

Authors:  S Romagnani
Journal:  Immunol Today       Date:  1991-08

Review 5.  Subsets of CD4+ T cells and their roles in the induction and prevention of autoimmunity.

Authors:  D Fowell; A J McKnight; F Powrie; R Dyke; D Mason
Journal:  Immunol Rev       Date:  1991-10       Impact factor: 12.988

6.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes.

Authors:  F Rousset; E Garcia; T Defrance; C Péronne; N Vezzio; D H Hsu; R Kastelein; K W Moore; J Banchereau
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

Review 7.  Interleukin 10: an overview.

Authors:  D Rennick; D Berg; G Holland
Journal:  Prog Growth Factor Res       Date:  1992

8.  Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation.

Authors:  D De Groote; P F Zangerle; Y Gevaert; M F Fassotte; Y Beguin; F Noizat-Pirenne; J Pirenne; R Gathy; M Lopez; I Dehart
Journal:  Cytokine       Date:  1992-05       Impact factor: 3.861

9.  IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.

Authors:  D F Fiorentino; A Zlotnik; P Vieira; T R Mosmann; M Howard; K W Moore; A O'Garra
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

10.  Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood: II. Application to rheumatoid arthritis and osteoarthritis.

Authors:  P F Zangerle; D De Groote; M Lopez; R J Meuleman; Y Vrindts; F Fauchet; I Dehart; M Jadoul; D Radoux; P Franchimont
Journal:  Cytokine       Date:  1992-11       Impact factor: 3.861

View more
  77 in total

Review 1.  Cytokines and systemic lupus erythematosus.

Authors:  G S Dean; J Tyrrell-Price; E Crawley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

2.  The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus.

Authors:  J Tyrrell-Price; P M Lydyard; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  Aberrant expression of soluble co-stimulatory molecules and adhesion molecules in type 2 diabetic patients with nephropathy.

Authors:  C K Wong; Amy W Y Ho; Peter C Y Tong; C Y Yeung; Juliana C N Chan; Alice P S Kong; Christopher W K Lam
Journal:  J Clin Immunol       Date:  2007-11-17       Impact factor: 8.317

4.  Increased lipid and protein oxidation and lowered anti-oxidant defenses in systemic lupus erythematosus are associated with severity of illness, autoimmunity, increased adhesion molecules, and Th1 and Th17 immune shift.

Authors:  Bruna Miglioranza Scavuzzi; Andréa Name Colado Simão; Tatiana Mayumi Veiga Iriyoda; Marcell Alysson Batisti Lozovoy; Nicole Perugini Stadtlober; Lorena Flor da Rosa Franchi Santos; Tamires Flauzino; Fabiano Aparecido de Medeiros; Marcelo Cândido de Sá; Luana Consentin; Edna Maria Vissoci Reiche; Michael Maes; Isaias Dichi
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

5.  Dynamic changes in the numbers of different subsets of peripheral blood NK cells in patients with systemic lupus erythematosus following classic therapy.

Authors:  Hongshuang Ma; Ling Zhao; Zhenyu Jiang; Yanfang Jiang; Li Feng; Zhuang Ye
Journal:  Clin Rheumatol       Date:  2014-07-15       Impact factor: 2.980

6.  Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE.

Authors:  J Rönnelid; A Tejde; L Mathsson; K Nilsson-Ekdahl; B Nilsson
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

7.  T cell activation by terminal complex of complement and immune complexes.

Authors:  Anil K Chauhan; Terry L Moore
Journal:  J Biol Chem       Date:  2011-09-07       Impact factor: 5.157

8.  Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity.

Authors:  C K Wong; Purple T Y Wong; L S Tam; Edmund K Li; D P Chen; Christopher W K Lam
Journal:  J Clin Immunol       Date:  2009-09-23       Impact factor: 8.317

Review 9.  Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus.

Authors:  E Kassi; P Moutsatsou
Journal:  J Biomed Biotechnol       Date:  2010-06-10

10.  Stage dependent aberrant regulation of cytokine-STAT signaling in murine systemic lupus erythematosus.

Authors:  Matthew B Hale; Peter O Krutzik; Shamsher S Samra; Janelle M Crane; Garry P Nolan
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.